The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: In Vivo evidence from patients with advanced non-small cell lung cancer (NSCLC)

Anticancer Research

Volumn 22, Issue 4, 2002, Pages 2073-2076

  Jumper, Cynthia ^a   Cobos, Everardo ^a   Lox, Charles ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

HER 2 neu; NSCLC; uPA; uPAR

Indexed keywords

PROTEIN P105; UROKINASE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; ENZYME DEGRADATION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; HEMOSTASIS; HUMAN; LUNG NON SMALL CELL CANCER; MALE; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; RECEPTOR UPREGULATION;

CARCINOMA, NON-SMALL-CELL LUNG; GENES, ERBB-2; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RECEPTORS, CELL SURFACE; REFERENCE VALUES; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036335984     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer
2. HER-2/neu expression in archival non-small cell lung carcinoma kusing FDA-approved Hercep test
3. Up-regulation of urokinase-type plasminogen activator expression by the HERI/neu proto-oncogene
4. Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma
5. Relation between blood coagulability and prognosis in patients with ovarian cancer. Nippon Sanka
6. The concentration of tissue plasminogen activator and urokinase in plasma and tissue of patients with ovarian and uterine tumors
7. Components of the plasminogen-plasmin system in human tumor cell lines
8. Serum levels of CerbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases
9. The role of the HER-2/neu oncogene in gynecologic cancers
10. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
11. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapyy in node-positive breast cancer patients
12. Serum levels of HER-2/neu (C-erbB-2) correlate with overexpression of p185 in human ovarian cancer
13. Elevated serum levels of c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy
14. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells. SK-BR-3
15. Prognostic significance of p 105 (c-erbB-2, HER-2/neu) serum levels in patients with ovarian cancer
16. Clinical use of serum c-erbB-2 in patients with ovarian masses
17. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors
18. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta integrin
19. Urokinase plasminogen activator in ovarian cancer
20. Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation
21. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties
22. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung
23. Genetic evolutionary staging of early non-small cell lung cancer: The p53-Her-2/NEU-ras sequence
24. Multiple molecular marker testing (p53, C-Ki-ras, c-erB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer
25. Ploidy, expression of erB1, erB2, P53 and amplification of erB1, erB2, and erB3 in non-small cell lung cancer
26. Serial serum cerB-2 levels in patients with breast carcinoma